Key statistics
On Thursday, Elicio Therapeutics Inc (ELTX:NAQ) closed at 8.41, 82.83% above the 52 week low of 4.60 set on Apr 09, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 8.40 |
|---|---|
| High | 8.70 |
| Low | 8.05 |
| Bid | 8.05 |
| Offer | 13.53 |
| Previous close | 8.40 |
| Average volume | 197.84k |
|---|---|
| Shares outstanding | 17.49m |
| Free float | 11.06m |
| P/E (TTM) | -- |
| Market cap | 146.91m USD |
| EPS (TTM) | -3.15 USD |
Data delayed at least 15 minutes, as of Feb 12 2026 21:00 GMT.
More ▼
Announcements
- Elicio Therapeutics Reports Inducement Grants
- Elicio Therapeutics Reports Inducement Grants
- Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial
- Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer
- Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
- Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC
- Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting
- Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial
- Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma
- Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial
More ▼
